Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

About Janssen Biotech, Inc.

Janssen Biotech, Inc. redefines the standard of care in immunology, oncology, urology and nephrology.  Built upon a rich legacy of innovative firsts, Janssen Biotech has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Beyond its innovative medicines, Janssen Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care. For more information on Janssen Biotech, Inc. or its products, visit www.janssenbiotech.com.

Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to people throughout the world.  Follow us on Twitter at www.twitter.com/JanssenUS.

(This press release contains "forward-looking statements" as defined in the Pr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
(Date:10/22/2014)... 2014   Reproductive Medicine Associates of New ... field of infertility, presents new clinical research examining ... research abstract, released during the 70 th ... in Honolulu, Hawaii , combines ... (SGD) pre-implantation genetic diagnosis (PGD). Results ...
(Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... research suggests that testosterone replacement therapy for men with ... the prostate gland, contrary to some reports that this ... the November 15 issue of JAMA, a theme issue ... of the Urological Sciences Research Foundation and University of ...
... completely prevented the development of bone tumors in 50 ... providing early evidence that it could treat, or thwart, ... a number of cancers when they start to spread. ... D. Anderson Cancer Center reported in the journal Cancer ...
... symptoms who received a combination therapy were more likely to ... medication, according to a study in the November 15 issue ... ,Steven A. Kaplan, M.D., of Weill Cornell Medical College, ... a JAMA media briefing on men's health in New York. ...
... Family Welfare Minister has said that to shut out ... name of safety would be// against the interest of ... two day International Conclave on Traditional Medicine, which he ... society we live in today, a significant segment of ...
... been sequencing the genome of an organism called Mycobacterium-w ... complete// genome that holds promise in the treatment of ... evidence that a vaccine made from killed Mw drastically ... resistant (MDR) variety is driving this project more than ...
... medical research team looking for a cure for Duchenne Muscular ... submitted their findings// recently. ,The Stem cell Studies ... hope for those who suffer from the disease. ... genetic origin that results in muscle wasting which usually ...
Cached Medicine News:Health News:Testosterone Replacement Therapy Appears Safe for Prostate 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 2Health News:"Trojan Horse" Agent Halts Bone Metastasis in Mice 3Health News:Combination Therapy More Effective for Treating Lower Urinary Tract Symptoms 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 2Health News:Two Day International Conclave on Traditional Medicine Inaugurated 3Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3
... drainage from the ureteropelvic junction to the ... ease of placement and patient compliance. The ... repositioning and ease of removal. AQ® is ... when activated, attracts and holds water and ...
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
Medicine Products: